Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Classical hematology 3Sarcoma 1Head & Neck 1

Conditions

Venous Thromboembolism 1Sarcoma 1Hematoma 1Bone Neoplasms 1

Interventions

Imatinib Mesylate 3nilotinib 2Sunitinib 2Ibandronic Acid 2Doxorubicin 2Cyclophosphamide 2regorafenib 1pegylated granulocyte colony-stimulating factor 1nirogacestat 1avapritinib 1anlotinib 1Zoledronic Acid 1Tranexamic Acid 1Thiotepa 1Ritonavir 1Radiotherapy 1Pregabalin 1Oxaliplatin 1Nevirapine 1Midazolam 1Lopinavir 1Lithium Carbonate 1Lead 1Kyphoplasty 1Indocyanine Green 1Ifosfamide 1Hyperbaric Oxygenation 1Filgrastim 1Esomeprazole 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Enoxaparin × Sarcoma × Clear all
NCT03244020 2025-10-03

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

Massachusetts General Hospital

Phase 4 Enrolling by invitation
2,868 enrolled
Classical hematologySarcoma

Bone Neoplasms, Hematoma, Sarcoma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡